PepGen's shares plummet 65% as mixed Phase 2 data sparks concern.

Tuesday, Mar 31, 2026 12:22 pm ET1min read
PEPG--

PepGen's shares have plummeted 65% after releasing mixed Phase 2 data. Despite the disappointing results, a higher dose may offer some relief. The company's shares dropped sharply yesterday and continue to fall today, making it one of the biggest losers in the market. The mixed data has raised concerns about the efficacy of PepGen's treatment.

PepGen's shares plummet 65% as mixed Phase 2 data sparks concern.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet